Inflammatory Pathways in Diabetes Biomarkers and Clinical Correlates /

This book discusses recent advances in new anti- and pro-inflammatory pathways in diabetic disease, and identifies new diagnostic immunological methods that offer potential companion diagnostics for diabetic diseases. New methods in proteomics, mass spectroscopy, immunological assay design, measurem...

Full description

Corporate Author: SpringerLink (Online service)
Other Authors: Pugia, Michael. (Editor, http://id.loc.gov/vocabulary/relators/edt)
Language:English
Published: Cham : Springer International Publishing : Imprint: Springer, 2015.
Edition:1st ed. 2015.
Series:Progress in Inflammation Research,
Subjects:
Online Access:https://doi.org/10.1007/978-3-319-21927-1
LEADER 04741nam a22005655i 4500
001 978-3-319-21927-1
003 DE-He213
005 20210617151829.0
007 cr nn 008mamaa
008 151020s2015 gw | s |||| 0|eng d
020 |a 9783319219271  |9 978-3-319-21927-1 
024 7 |a 10.1007/978-3-319-21927-1  |2 doi 
050 4 |a QR180-189.5 
072 7 |a MJCM  |2 bicssc 
072 7 |a MED044000  |2 bisacsh 
072 7 |a MJCM  |2 thema 
082 0 4 |a 616.079  |2 23 
245 1 0 |a Inflammatory Pathways in Diabetes  |h [electronic resource] :  |b Biomarkers and Clinical Correlates /  |c edited by Michael Pugia. 
250 |a 1st ed. 2015. 
264 1 |a Cham :  |b Springer International Publishing :  |b Imprint: Springer,  |c 2015. 
300 |a XVI, 219 p. 33 illus., 18 illus. in color.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
490 1 |a Progress in Inflammation Research,  |x 0379-0363 
505 0 |a Part 1. Introduction -- 1. Impact of inflammation and the innate immunity response in obesity mediated diabetes (lit review) -- Part 2. Impact of complement on diabetic disease -- 2. Complement and Complement Regulatory Proteins in Diabetes -- Part 3. Role of C terminal fragment of adiponectin receptor in inhibition of insulin degradation -- 3. Development of adiponectin receptor C terminal fragment bioassays -- 4. Protease inhibition and biological distribution of the C terminal fragment of adiponectin receptor -- 5. Cell & biological models for the C terminal fragment of adiponectin receptor -- 6. C-Terminal fragment of adiponectin receptor clinical correlations -- Part 4. Uristatin assay for prediction of renal and other clinical events -- 7. Uristatin immunoassay usage in glomerular nephritis assessment -- 8. Acute Response of Uristatin in Surgery -- 9. Cardiovascular and metabolic syndrome impact on uristatin -- 10. Uristatin anti-inflammatory cellular signaling -- Part 5. Summary -- 11. Overview of progress in new markers for diabetes inflammation (Literatue Review). 
520 |a This book discusses recent advances in new anti- and pro-inflammatory pathways in diabetic disease, and identifies new diagnostic immunological methods that offer potential companion diagnostics for diabetic diseases. New methods in proteomics, mass spectroscopy, immunological assay design, measurement of cellular signal transduction and protease inhibition are used to clarify new biochemical pathways. Biomarker validation in animal models and correlations in humans for diagnostic clinical trials shed new light on the impact of diabetic diseases. The book reviews current understanding of inflammatory pathways in the pathophysiology of insulin resistance, metabolic syndrome, nephritis and other diabetic inflammatory conditions, and is the first to describe the impact of novel adipokines, protease inhibitors and complement markers. By presenting new methodologies for biomarker discovery, it provides a valuable resource for researchers studying clinical diagnosis, drug development, bio-analytical chemistry, proteomics and biochemistry. It is also useful for those conducting clinical and biological studies for targeted drug development. The methodologies and approaches can be applied to other markers, and the information will be helpful in the preparation of research grant applications. 
650 0 |a Immunology. 
650 0 |a Diabetes. 
650 0 |a Pharmacology. 
650 0 |a Metabolic diseases. 
650 0 |a Biochemistry. 
650 1 4 |a Immunology.  |0 https://scigraph.springernature.com/ontologies/product-market-codes/B14000 
650 2 4 |a Diabetes.  |0 https://scigraph.springernature.com/ontologies/product-market-codes/H33045 
650 2 4 |a Pharmacology/Toxicology.  |0 https://scigraph.springernature.com/ontologies/product-market-codes/B21007 
650 2 4 |a Metabolic Diseases.  |0 https://scigraph.springernature.com/ontologies/product-market-codes/H33118 
650 2 4 |a Biochemistry, general.  |0 https://scigraph.springernature.com/ontologies/product-market-codes/L14005 
700 1 |a Pugia, Michael.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer Nature eBook 
776 0 8 |i Printed edition:  |z 9783319219288 
776 0 8 |i Printed edition:  |z 9783319219264 
776 0 8 |i Printed edition:  |z 9783319372815 
830 0 |a Progress in Inflammation Research,  |x 0379-0363 
856 4 0 |u https://doi.org/10.1007/978-3-319-21927-1 
912 |a ZDB-2-SBL 
912 |a ZDB-2-SXB 
950 |a Biomedical and Life Sciences (SpringerNature-11642) 
950 |a Biomedical and Life Sciences (R0) (SpringerNature-43708)